Drug Profile
Solitomab - Amgen
Alternative Names: AMG-110; Anti-CD3 anti-EpCAM bispecific antibody - Amgen; MT110; MT110 monoclonal antibody; SolitumomabLatest Information Update: 24 Apr 2016
Price :
$50
*
At a glance
- Originator Micromet Inc
- Developer Amgen
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 01 Jan 2015 Amgen completes a phase I trial of solitomab in Solid tumours in Germany (NCT00635596)
- 07 Mar 2012 Micromet Inc has been acquired by Amgen
- 08 Jun 2010 Interim efficacy & adverse events data from a phase I trial of IV solitomab in Solid tumours (lung, gastrointestinal) presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010)